Asit C Mehta is bullish on Piramal Pharma has recommended buy rating on the stock with a target price of Rs 171 in its research report dated April 01 2024.
Going ahead to the current week starting from April 1, close attention will be paid to the all-time high levels above 22,500, as hesitation was evident at these levels.
Piramal Pharma has negated lower highs formation seen in previous 11 consecutive sessions and saw gap up opening on Tuesday. The stock formed bullish candlestick pattern with long upper shadow on the daily charts.
Motilal Oswal is bullish on Piramal Pharma recommended buy rating on the stock with a target price of Rs 165 in its research report dated January 31, 2024.
